FAQ/Help |
Calendar |
Search |
Today's Posts |
![]() |
#1 | ||
|
|||
News Gatherer
Community Support Team
|
Sep 1, 2010 - In a study published this week by Majestic Research , almost 60% of neurologists expressed unaided concern about the side effects/safety of oral MS therapies in development, including NVS's Gilenia and MRK/EMD Serono's oral cladribine.
More... (From Topix Neurology) |
||
![]() |
![]() |
Reply |
Thread Tools | |
Display Modes | |
|
|
![]() |
||||
Thread | Forum | |||
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA | Multiple Sclerosis |